---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-117809"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:39:46.279816+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atea Pharma Q1 net loss narrows to $34.3M; cash $425M; Phase 3 HCV trial enrolling

## Summary
- Net loss $34.3M ($0.40/share) vs $63.2M ($0.75) in Q1 2024; R&D expense down 49% to $29.6M.
- Cash, equivalents and marketable securities $425.4M at March 31, down from $454.7M at Dec 31.
- Phase 3 C-BEYOND HCV trial enrolling; second Phase 3 C-FORWARD expected mid-2025.
- Strategic alternatives review with Evercore ongoing; workforce reduced ~25% to save ~$15M through 2027.
- Board authorized $25M share repurchase; Arthur Kirsch and Howard Berman appointed to board.

## SEC filing metadata
- accession: 0001193125-25-117809
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312525117809/0001193125-25-117809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312525117809/d923851d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-117809
- JSON: https://secwatch.observer/filing/0001193125-25-117809.json
- Plain text: https://secwatch.observer/filing/0001193125-25-117809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.